Search

Your search keyword '"William P. McGuire"' showing total 127 results

Search Constraints

Start Over You searched for: Author "William P. McGuire" Remove constraint Author: "William P. McGuire"
127 results on '"William P. McGuire"'

Search Results

51. Taxol: A New Drug with Significant Activity as a Salvage Therapy in Advanced Epithelial Ovarian Carcinoma

53. Phase I trial results of a folate receptor alpha-directed cancer vaccine (E39) in ovarian and endometrial cancer patients to prevent recurrence

54. Intraperitoneal Therapy for Ovarian Cancer: A Sacrifice Bunt

55. Intraocular manifestations on acute disseminated lupus erythematosus

57. Sequences of taxol and cisplatin: a phase I and pharmacologic study

58. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?

59. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study

60. Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer

61. Differences in presentation and survival of Asians versus Caucasians with ovarian cancer: A Gynecologic Oncology Group ancillary study of 7914 patients

62. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens

63. How many more nails to seal the coffin of dose intensity?

64. Recurrent ovarian cancer

65. Liposomal anthracycline treatment for ovarian cancer

66. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks

67. Progress in the management of gynecologic cancer: consensus summary statement

68. Phase II study of Ifosfamide and Mesna in refractory adenocarcinoma of the endometrium

69. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis

70. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: A Gynecologic Oncology Group study

71. Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence

72. Patient-Derived Xenografts Accurately Capture Clinical Responses to Treatment

73. Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy

74. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study

75. Another Confirmation of the Inactivity of Topotecan in Ovarian Cancer

76. Assessing the Effect of Response on Survival in Ovarian Cancer

77. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study

78. Ovarian Cancer, CA-125 Addiction, and Informed Confusion: Much Ado About Less

79. Progress in the Management of Gynecologic Cancer

80. High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors

81. Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system

82. CASE 1. Testis: A Sanctuary Site in Merkel Cell Carcinoma

83. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study

84. Abstract 3377: Integrated molecular analysis of ovarian cancer cells identifies the ATR signaling axis central to cisplatin resistance

85. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study

86. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

87. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

88. Options for primary chemotherapy of epithelial ovarian cancer: taxanes

89. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

90. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience

91. Weekly topotecan in patients with platinum-sensitive and platinum-resistant recurrent ovarian and peritoneal cancers

92. Synchronous mature teratomas of the ovary and liver: a case presenting 11 years following chemotherapy for immature teratoma

93. Anaphylaxis to carboplatin--a new platinum chemotherapeutic agent

95. Cardiac disturbances during the administration of taxol

96. Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination

97. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma

98. Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group

99. Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance

100. Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer

Catalog

Books, media, physical & digital resources